Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1418||SWOG||A Randomized; Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1500||SWOG||A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1501||SWOG||Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer; Phase III||Cancer Prevention and Control CIRB||Available to Open|
|S1505||SWOG||A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1507||SWOG||A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1512||SWOG||A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1513||SWOG||Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1600||SWOG||A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes||Cancer Prevention and Control CIRB||Available to Open|
|S1602||SWOG||A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Nave High-Grade Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1605||SWOG||Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|